| 21/100 | US=89 / Biol/Mol Kang C, Pu P, Jiang H. Silencing epidermal growth factor receptor by RNA interference in glioma. In: Walther W, Stein US. Gene therapy of cancer: methods and protocols. 2ª ed. New Jersey: Humana Press, 2009. p. 335-49. (Methods in Molecular Biology, 542) ISBN 978-1-59745-561-9. RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INTERFERENCIA DE RNA; GLIOMA; EGFR; INVASAO; PROLIFERACAO; SIRNA |
| 22/100 | US=85 / Biol/Mol Kim SH, Kim SH, Song YC, Song YS. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 642-8. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. |
| 23/100 | US=96 / Biol/Mol Márquez-Garbán DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 194-205. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0. NSCLC; CYP19; EGFR; NAO-PEQUENAS CELULAS DE PULMAO; AROMATASE; RECEPTOR DE ESTROGENO; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DO FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; ANASTRAZOLE; EXEMESTANO; FULVESTRANT; VANDETANIB |
| 24/100 | US=97 / Biol/Mol Schneider V, Rischke HC, Drevs J. Tumor angiogenesis. In: Molls M, Vaupel P, Nieder C, Anscher MS. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Baltimore: Springer, 2009. p. 39-50. (Medical Radiology Radiation Oncology) ISBN 978-3-540-74385-9. ANGIOGENESE TUMORAL; VEGF; CRESCIMENTO TUMORAL; EGFR; SINALIZACAO INTRACELULAR; FISIOPATOLOGIA DA ANGIOGENESE; FISIOPATOLOGIA DA RADIACAO; SUBSTANCIAS ANTIANGIOGENICAS; QUIMIOTERAPIA; TERAPIA ANTIANGIOGENICA; RADIACAO |
| 25/100 | US=45-B / Cab/Pesc Smith BD, Haffty BG. Prognostic factors in patients with head and neck cancer. In: Harrison LB, Sessions RB, Hong WK. Head and neck cancer: a multidisciplinary approach. 3rd ed. Philadelphia: J B Lippincott, 2009. p. 51-75. ISBN 978-0-7817-7136-8. CANCER DE CABECA E PESCOCO; FATORES PROGNOSTICOS; NEOPLASIA PRIMARIA; LINFONODOS CERVICAIS; FATORES DEMOGRAFICOS; COMORBIDADE; ESTADO NUTRICIONAL; ANEMIA; FATORES PROGNOSTICOS MOLECULARES; P53; MARCADORES RELACIONADOS A ANGIOGENESE; CICLINA D1; RECEPTOR DO FACTOR DE CRESCIMENTO EPIDERMICO (EGFR) |
| 26/100 | US=13 / Biol/Mol Pecorino L. Growth factor signaling and oncogenes. In: ___. Molecular biology of cancer: mechanisms, targets, and therapeutics. 2nd ed. Oxford: Oxford University Press, 2008. p. 69-94. ISBN 978-0-19-921148-7. FATORES DE CRESCIMENTO; SINALIZACAO; ONCOGENES; FATOR DE CRESCIMENTO EPIDERMICO; AUTOFOSFORILACAO; TRANSLOCACAO DE PROTEINAS ESPECIFICAS; ATIVACAO DO GENE RAS; ATIVACAO DO GENE RAF; CASCATA DE MAP QUINASE; REGULACAO DOS FATORES DE TRANSCRICAO; SINALIZACAO CELULAR; COMPORTAMENTO CELULAR; RETROVIRUS; TRANSDUTORES DE SINAL INTRACELULAR; FATORES DE TRANSCRICAO; MECANISMOS DE ATIVACAO ONCOGENICA; INIBIDORES DA QUINASE; DROGAS ANTI-EGFR; DROGAS ANTI-RECEPTORES DO FATOR DE CRESCIMENTO EPIDERMICO |
| 27/100 | US=28 / Biol/Mol Grothey A. Antiangiogenesis agents in colorectal cancer. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 371-84. ISBN 978-1-58829-870-6. |
| 28/100 | US=23-A / Câncer Bartolazzi A. Non-small cell lung carcinoma: EGFR gene mutations and response to gefitinib. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 291-306. ISBN 978-1-4020-8441-62. CANCER; CANCER DE PULMAO; CANCER DE PULMAO DE NAO-PEQUENAS CELULAS; MUTACOES EGFR; GEFITINIBE; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO |
| 29/100 | US=53 / Biol/Mol Sandberg A, Stone JF. Key mechanisms and pathways. In: ___. The genetics and molecular biology of neural tumors. New Jersey: Humana Press, 2008. p. 431-43. ISBN 978-1-59745-510-7. TUMORES NEURAIS; VIAS MOLECULARES; TP53; RB; WNT; SHH; EGFR; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; TELOMERES; TELOMERASE; EPIGENETICA; CICLO CELULAR; APOPTOSE |
| 30/100 | US=67 / Biol/Mol Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2 |
| 31/100 | US=67 / Biol/Mol Ho C, Davies AM, Lara PN, Gautschi O, Mach PC, Gumerlock PH, Gandara DR. Untargeted use of targeted therapy: a dilemma in non-small cell lung cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 227-40. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; TERAPIA-ALVO; EGFR; VEGF; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL |
| 32/100 | US=67 / Biol/Mol Azad NS, Sarosy G, Kohn EC. Molecular targets in ovarian cancer and endometrial cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 291-308. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE OVARIO; CANCER ENDOMETRIAL; ALVOS MOLECULARES; TIROSINA-QUINASES; EGFR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ONCOGENE; GENES SUPRESSORES DE TUMOR |
| 33/100 | US=69 / Câncer Kopetz S. Targeted therapy in colorectal cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 101-23. ISBN 978-1-60327-423-4. TERAPIA-ALVO; CANCER COLORRETAL; EGFR; VEGF; ANTICORPOS MONOCLONAIS |
| 34/100 | US=69 / Câncer Stewart DJ. Targeted therapy in non-small cell lung cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 125-56. ISBN 978-1-60327-423-4. TERAPIA-ALVO; NAO-PEQUENAS DE CANCER DE PULMAO DE CELULAS; EGFR; ERLOTINIB; GEFITINIB; VEGFR |
| 35/100 | US=90 / Biol/Mol Burgess AW, Garrett TPJ. EGFR signaling networks: EGF receptor family extracellular domain structures and functions. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 3-14. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. ERBB2; ERBB3; ERBB4; 3-DIMENSIONAL ESTRUTURAS; TRANSICOES CONFORMACIONAIS; EPITOPOS DE ANTICORPOS |
| 36/100 | US=90 / Biol/Mol Stern HM. EGFR signaling networks: EGFR family heteroimers in cancer pathogenesis and treatment. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 15-30. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. |
| 37/100 | US=90 / Biol/Mol Eigenbrot C. EGFR signaling networks: structure-function of EGFR kinase domain and its inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 31-45. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. CRISTALOGRAFIA DE RAIOS X; INIBIDOR DE MOLECULA PEQUENA; ESCAPAR MUTACAO; ACTIVACAO DA CINASE; ALLOSTERY; L858R; T790M |
| 38/100 | US=90 / Biol/Mol Sorkin A. EGFR signaling networks: internalization and degradation of the EGF receptor. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 47-61. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EGF; RECEPTOR; ENDOCITOSE; CLATRINA; UBIQUITINACAO; DEGRADACAO; ENDOSSOMO; LISOSSOMA |
| 39/100 | US=90 / Biol/Mol Xu W, Neckers L. EGFR signaling networks: differential dependence of EGFR and ErbB2 on the molecular chaperone Hsp90. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 63-71. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. CHAPERONES MOLECULARES; PROTEINA DE CHOQUE TERMICO 90; ANSAMICINAS BENZOQUINONA; GELDANAMICINA; HSP90 INIBIDOR; MUTACOES DE EGFR; SENSIBILIDADE AO FARMACO |
| 40/100 | US=90 / Biol/Mol Koppikar P, Grandis JR. EGFR signaling networks: activation of STATs 3 and 5 through the EGFR signaling axis. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 73-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. |